Skip to Content

Posts tagged with "Toxicology"

  • Clinical Trials

    Big Trouble For Zafgen and Beloranib

    Zafgen went through a very rough patch back in October when it turned out that a patient in their key Phase III trial in Prader-Willi syndrome died. P-W patients have severe health problems and shortened lifespan, but the question was naturally whether the company’s investigational drug beloranib was a factor. The seemingly slow disclosure of… Read More
  • Cancer

    Another Funny-Looking Structure Comes Through

    Here’s one that I certainly wouldn’t have thought about doing. This recent paper in ACS Medicinal Chemistry Letters describes changing the substituents off the core of a PAK1 inhibitor. Nothing too interesting about that, you’d think: the inhibitor itself is one of your standard-looking kinase inhibitor sausage strings of heteroar… Read More
  • Clinical Trials

    The Wildly Unlikely Return of TGN1412

    You may be familiar with the bizarre story of TGN1412, an immunotherapy developed (briefly) by a small German company called TeGenero in 2006. This led to the infamous Phase I incident in England where a set of six volunteers were dosed at fifteen-minute intervals, but right after the last one got the injection, the first… Read More
  • Cardiovascular Disease

    PCSK9 In the Details

    The PCSK9 inhibitors are a class of drugs from which great things are expected. The first ones hitting the market are antibodies, and blocking this enzyme, which is involved in cholesterol homeostasis, clearly has major effects on circulating LDL levels. There are a lot of approaches to going after this target, in the lab, the… Read More
  • Drug Development

    Modeling the Rats, Who Model the Humans

    When you get down to it, one of the biggest problems in drug discovery is that there is (in most cases) no alternative but doing things the hard way. If you want to find out if your drug is going to work for a given disease, there’s no other way to be sure than to… Read More
  • Alzheimer's Disease

    Two Alzheimer’s Updates (Lilly and TauRx)

    When you look at the stock charts of the major pharma companies, there’s not a lot of excitement to be had. Until you get to Eli Lilly, that is. Over the last year, the S&P 500 is up about 5%, and most of the big drug stocks are actually negative (Merck -0.4%, Sanofi down 6%… Read More
  • Drug Assays

    The End of Compound Property Optimization Is At Hand

    Here’s another Big Retrospective Review of drug pipeline attrition. This sort of effort goes back to the now-famous Rule-of-Five work, and readers will recall the Pfizer roundup of a few years back, followed by an AstraZeneca one (which didn’t always recapitulate the Pfizer pfindings, either). This latest is a joint effort to look at th… Read More
  • Animal Testing

    Organ Models on Chips

    Why do we test new drug candidates on animals? The simple answer is that there’s nothing else like an animal. There are clearly chemical and biological features of living systems that we don’t yet understand, or even realize exist – the discovery of things like siRNAs is enough proof of that. So you’re not going… Read More
  • The Central Nervous System

    Sertraline in the Courts

    Potential trouble: thoughts of a link between cardiac birth defects and the antidepressant Zoloft (sertraline). Pfizer recently won such a case in Missouri, but the latest trial seems to have produced some internal documents that might lead to a different verdict. Since this is all in the context of lawsuits, the signal/noise (for an outside… Read More
  • Business and Markets

    Some Side Effect For An Antibody

    Remember back when AstraZeneca was fighting off Pfizer’s ardent, tax-issue-resolving embrace a year ago? One of their weapons was a pitch to their own shareholders about what potential their own pipeline had, and how much of that would presumably go to waste should the deal go through. Even at the time, people thought that their… Read More
...345...